NRX Pharmaceuticals (NRXP) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 0.9% versus a loss of 38.0%. Over five years, UNCY leads with a -88.5% price change compared with -96.8% for NRXP. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $95.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | UNCY |
|---|---|---|
| Share price | $2.15 | $3.35 |
| Market cap | $95.31M | $97.77M |
| 1-day change | -15.69% | -5.10% |
| YTD return | -20.66% | -41.94% |
| 1-year return | +0.94% | -37.96% |
| 5-year return | -96.81% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-0.33 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.23M | — |
| Net income (latest FY) | $-28.62M | $-26.55M |
| Gross margin | 58.78% | — |
| Operating margin | -1324.41% | — |
| Net margin | -2336.49% | — |
| 52-week high | $5.06 | $8.74 |
| 52-week low | $1.62 | $3.33 |
| Distance from 52-week high | -57.47% | -61.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1702.33% | +685.07% |
| Average volume | 1.07M | 963.80K |
| Shares outstanding | 44.33M | 29.18M |
| Employees | 29 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed UNCY by 38.9 percentage points over the past year.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NRXP vs UNCY FAQ
Which is bigger, NRX Pharmaceuticals or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $95.31M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, NRXP or UNCY?
NRXP returned +0.94% over the past 12 months, compared with -37.96% for UNCY (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.